Side by side
GHRP-2 vs IGF-1 LR3
Both are discussed for muscle & performance. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.
| GHRP-2 | IGF-1 LR3 | |
|---|---|---|
| What it is | A growth hormone releasing peptide approved in Japan as a diagnostic agent. It triggers a pulse of your own growth hormone rather than supplying any. | A modified insulin-like growth factor engineered to last far longer in the body than the natural hormone. It can cause hypoglycaemia, which makes it the most acutely dangerous compound on this site. |
| EvidenceHow much human evidence exists, not how well it works. | Approved for another indication | Preclinical |
| Regulatory statusReviewed 2026-08-16 | Approved in Japan as pralmorelin, a single-dose diagnostic agent for growth hormone deficiency. Not approved anywhere for repeated use to raise growth hormone, and not approved in the United States for any indication. Material sold as a research chemical is not the approved product. | Not approved for human use in any jurisdiction, and never studied in a human trial. Recombinant IGF-1 itself (mecasermin) is approved for severe primary IGF-1 deficiency, and its labelling carries an explicit hypoglycaemia warning. That warning is the closest thing to clinical safety information this class has. |
| Routes | Subcutaneous | Subcutaneous, Intramuscular |
| Half-life | 0.5 hours | 24 hours |
| Cheapest per mgVials only, read from vendors' own listings and dated on the price index. | $1.20/mg | $32.50/mg |
| Median per mg | $3.70/mg | $79.00/mg |
| Vendors with a price | 16 | 32 |
| Storage once mixed | Refrigerated at 2–8 °C. Do not freeze once mixed. | Refrigerated at 2–8 °C. Do not freeze once mixed. Larger proteins are less forgiving of temperature swings than short peptides. |
Compare two other compounds · The full price index
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.